

## QUALIFICATION CERTIFICATE

I, Christopher Moreau, Chief Executive Officer of Algernon Pharmaceuticals Inc. (the “**Issuer**”), hereby certify that:

- (a) the Issuer is entitled to file a preliminary short form prospectus under National Instrument 44-101 in each of the provinces of Alberta, British Columbia, Manitoba and Ontario, by virtue of the Issuer satisfying the requirements of Section 2.2 of the Instrument; and
- (b) all of the material incorporated by reference in the preliminary short form prospectus and not previously filed is being filed with the preliminary short form prospectus.

DATED: June 1, 2020

**ALGERNON PHARMACEUTICALS INC.**

“Christopher Moreau”  
Christopher Moreau  
Chief Executive Officer